ClinicalTrials.gg
RecruitingNCT03579875Updated Jan 30, 2026

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

A Phase 2 interventional study of Total Body Irradiation (TBI) (Plan 1) and Cyclophosphamide (CY) (Plan 1) in Fanconi Anemia, Severe Aplastic Anemia and Myelodysplastic Syndromes, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2018; still recruiting 8 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
Up to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing cyclophosphamide in Fanconi Anemia — 2 open to participants now, 2 under way, none of them phase 3. Cyclophosphamide · Fanconi Anemia.

Planned enrollment
3rd of 14
48 · median 28
Started
2018
with 1 other
Phase 2
7 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
4 of 16
Masonic Cancer Center, University of Minnesota

Among the 16 studies testing cyclophosphamide in Fanconi Anemia, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2018, is one of 7 in phase 2, and was the 15th registered.

Fanconi Anemia

95 studies on the registry are indexed under Fanconi Anemia; 20 are open to participants now.

Browse Fanconi Anemia studies →

Open to participants now

2 of the 16 studies testing cyclophosphamide in Fanconi Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 15 Fanconi Anemia studies recruiting now, 8 (53%) set no upper age limit and 4 (27%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: Up to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing cyclophosphamide in Fanconi Anemia, or all of them as a file.
02

Study summary

This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.

03

Conditions studied

  • Fanconi Anemia
  • Severe Aplastic Anemia
  • Myelodysplastic Syndromes
  • T Cell Receptor Alpha/Beta Depletion
  • Telomere Biology Disorder
  • Bone Marrow Failure
  • Dyskeratosis Congenita
  • Telomere Biology Disorders
04

Who can participate

Ages eligible
Up to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Patient Selection:

Inclusion criteria

Inclusion Criteria:

For FA patients:

  • Diagnosis of Fanconi anemia

    • Age \<65 years of age
  • Has one of the following risk factors:

    • Severe aplastic anemia (SAA)
    • Myelodysplastic features
    • High risk genotype
    • Immunodeficiency associated with history of recurrent infections
  • performance status ≥ 70% if ≥ 16 years of age or Lansky play score ≥ 50% for patients \<16 years of age

    • Adequate pulmonary, cardiac and liver function
    • Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care

For TBD patients:

  • Diagnosis of TBD
  • Age \<70 years of age
  • Has one of the following risk factors:
  • Severe aplastic anemia (SAA)
  • Myelodysplastic features
  • Karnofsky performance status ≥ 70% if ≥ 16 years of age or Lansky play score

    ≥ 50% for patients \<16 years of age

  • Adequate pulmonary, cardiac and liver function
  • Voluntary written consent (minor assent if appropriate) prior to the performance of any study related procedures not part of standard medical care

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding as the treatment used in this study are Pregnancy Category D. Females of must have a negative pregnancy test (serum or urine) within 14 days of study registration
  • Active, uncontrolled infection within 1 week prior to starting study therapy
  • Malignant solid tumor cancer within previous 2 years

Donor Selection (Inclusion Criteria): meets one of the following match criteria:

  • an HLA-A, B, DRB1 matched sibling donor (matched sibling)
  • an HLA-A, B, DRB1 matched related donor (other than sibling)
  • a related donor mismatched at 1 HLA-A, B, C and DRB1 antigen
  • 7-8/8 HLA-A,B,C,DRB1 allele matched unrelated donor per current institutional guidelines Patients and donors are typed for HLA-A and B using serological or molecular techniques and for DRB1 using high resolution molecular typing. If a donor has been selected on the basis of HLA-A, B, C and DRB1 typing as above, preference will be made for donors matched at the HLA-C locus.
  • Body weight of at least 40 kilograms and at least 12 years of age
  • Willing and able to undergo mobilized peripheral blood apheresis
  • In general good health as determined by the medical provider
  • Adequate organ function defined as:

    • Hematologic: , WBC, within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)
    • Hepatic: \< 2 x
    • Renal: serum creatinine \< 1.8 mg/dl
  • Performance of a donor infectious disease screen panel including CMV Antibody, Surface Antigen, Hepatitis B Core Antibody, Antibody, 1/2 Antibody, HTLVA 1/2 Antibody, Treponema, and Trypanosoma Cruzi (T. Cruzi) plus HBV, HCV, WNV, HIV by nucleic acid testing (NAT); and screening for evidence of and risks factors for infection with Zika virus, or per current standard institutional donor screen - must be negative for HIV and active hepatitis B
  • Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of mobilization start
  • Voluntary written consent (parent/guardian and minor assent, if \< 18 years) prior to the performance of any research related procedure
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Treatment Plan 1: TBI 300 , CY, FLU, MP, Rituximab in patients with Fanconi Anemia

    Given to: * Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR * Patients with an HLA- identical sibling donor recipient and myelodysplastic features, MDS, or acute leukemia

    Drug: Total Body Irradiation (TBI) (Plan 1) · Drug: Cyclophosphamide (CY) (Plan 1) · Drug: Fludarabine (FLU) · Drug: Methylprednisolone (MP) · Device: Donor mobilized PBSC infusion · Drug: G-CSF · Drug: Rituximab

  • Experimental
    Treatment Plan 2: CY, FLU, MP, Rituximab in patients with Fanconi Anemia

    Given to: • An HLA-identical sibling donor recipients with single or multi- lineage hematopoietic failure

    Drug: Fludarabine (FLU) · Drug: Methylprednisolone (MP) · Device: Donor mobilized PBSC infusion · Drug: G-CSF · Drug: Cyclophosphamide (CY) (Plan 2) · Drug: Rituximab

  • Experimental
    Treatment Plan 3: BU, Cy, FLU, MP and Rituximab in patients with Fanconi Anemia

    Given to: * Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI * Patients with an HLA- identical sibling donor recipient and myelodysplastic features, MDS, or acute leukemia who cannot tolerate TBI * Biallelic mutations in FANCD1/BRCA2 who cannot receive TBI * Per treating physician preference

    Drug: Cyclophosphamide (CY) (Plan 1) · Drug: Fludarabine (FLU) · Drug: Methylprednisolone (MP) · Drug: Rituximab · Drug: Busulfan

  • Experimental
    Treatment Plan 4: CY, FLU, and alemtuzumab

    given to TBD patients with: * Bone marrow failure AND * Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 3 patients would be treated per year. Statistical outcomes will be descriptive.

    Drug: Cyclophosphamide (CY) (Plan 1) · Drug: Fludarabine (FLU) · Drug: Alemtuzumab

  • Experimental
    Treatment Plan 5: CY, FLU, melphalan (MEL), and alemtuzumab.

    given to TBD patients with: * Early myelodysplastic features (with or without cytogenetic abnormalities) AND * Any donor type including haploidentical (4/8) to 8/8-HLA matched related donor, or 7-8/8 HLA-matched unrelated donor Based on historical numbers, it is expected approximately 2 patients would be treated per year. Statistical outcomes will be descriptive.

    Drug: Cyclophosphamide (CY) (Plan 1) · Drug: Fludarabine (FLU) · Drug: Alemtuzumab · Drug: Melphalan

Interventions

  • DrugTotal Body Irradiation (TBI) (Plan 1)

    300 cGy with thymic shielding on day -6

    Also known as: TBI

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10 mg/kg IV daily on days -5, -4, -3, and -2

    Also known as: CY

  • DrugFludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    35 mg/m2 IV daily on days -5, -4, -3, and -2

    Also known as: FLU

  • DrugMethylprednisoloneStudies of MethylprednisoloneMethylprednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 mg/kg IV q12h on days -5, -4, -3, -2, and -1

    Also known as: MP

  • DeviceDonor mobilized PBSC infusion

    T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0

    Also known as: PBSC

  • DrugGranulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days or single day ANC \>3000 Arm 1 and Arm 3)

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5 mg/kg IV daily on days -5, -4, -3, and -2

    Also known as: CY

  • 200 mg/m2 IV once on day -1

  • Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.

    Also known as: BU

  • Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)

  • If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.

    Also known as: MEL

  • Rituximab will be given once on treatment plans 1-3 on day -1.

06

What researchers measure

Primary outcomes

  1. Grade II-IV acute graft versus host disease (GVHD)

    incidence of grade II-IV acute graft versus host disease (GVHD)

    Time frame: Day 100

Secondary outcomes

  1. Neutrophil engraftment

    Rate of neutrophil engraftment (defined as the first of three consecutive days after HCT that the patient's absolute neutrophil counts is ≥ 0.5x109 per liter)

    Time frame: Day 42

  2. Platelet engraftment

    Time to platelet engraftment (First of three consecutive days after HCT that the patient's platelet count ≥ 20x10\^9 per liter)

    Time frame: Day 42

  3. Acute graft versus host disease (aGVHD)

    Incidence of grade III-IV acute graft versus host disease

    Time frame: Day 100

  4. Chronic graft versus host disease (cGVHD)

    Incidence of chronic graft versus host disease after transplant

    Time frame: 1 Year after transplant

  5. Regimen related toxicity

    Incidence of regimen related toxicity based on CTCAE v5

    Time frame: 30 Days after transplant

  6. Bacterial, viral and fungal infections

    Incidence of bacterial, viral and fungal infections

    Time frame: 1 Year after transplant

  7. Opportunistic infections

    Incidence of opportunistic infections

    Time frame: 100 Days after transplant

  8. Overall survival (OS)

    Incidence of overall survival

    Time frame: 1 Year after transplant

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for Jan 2027, 97 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2018
First posted
Jul 9, 2018
StartActual
Nov 13, 2018
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 5, 2029
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03579875
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
Nov 13, 2018
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 5, 2029 (estimated)
Last update
Jan 30, 2026

Study contacts

Margaret MacMillan, MD, Msc, FRCPC
Contact
macmi002@umn.edu
612-626-2961
Margaret MacMillan, MD, Msc, FRCPC
principal investigator · Masonic Cancer Center, University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Methylprednisolone · Granulocyte Colony-Stimulating Factor · Rituximab · Busulfan · Alemtuzumab · Melphalan

Start the discussion